2 Years of Endocrine Therapy, 2 Decades of Protection From Metastatic Breast Cancer
(MedPage Today) -- Two years of adjuvant endocrine therapy for premenopausal breast cancer protected against metastatic recurrence for 20 years, a new analysis of a randomized trial showed.
Premenopausal women who received goserelin, tamoxifen...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hematology | Tamoxifen | Women